Clinical Trials Logo
  1. Home
  2. Hypertrophic Cardiomyopathy
  3. NCT06434415
  4. Details
NCT06434415 Clinical Trial

Prognostic Value of Coronary Angiography-Derived Index of Microcirculatory Resistance in Hypertrophic Cardiomyopathy Patients

Hypertrophic Cardiomyopathy Clinical Trial

Official title:
Prognostic Value of Coronary Angiography-Derived Index of Microcirculatory Resistance in Hypertrophic Cardiomyopathy Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT06434415
Other study ID # 2024005
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2017
Est. completion date May 31, 2024

Study information
Verified date May 2024
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Coronary microvascular dysfunction (CMD) is among pathophysiological states of significance in hypertrophic cardiomyopathy (HCM). The index of microcirculatory resistance (IMR) has been recognized as an indicator of CMD and considered of important prognostic value in various conditions. The angiography-derived index of microcirculatory resistance (angio-IMR) is a novel guidewire-free method to assess IMR and proved to have favourable correlation with it. This study was designed to assess prognostic impact of CMD in HCM patients, using angio-IMR as a novel non-invasive assessment tool.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 470
Est. completion date May 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. diagnosed with hypertrophic cardiomyopathy(HCM) based on clinical guidelines 2. have qualified image for analysis of angio-IMR Exclusion Criteria: 1. referred to hospital due to ST-segment elevation myocardial infarction(STEMI), heart failure and cardiopulmonary arrest; 2. severe valve dysfunction; 3. history of implantation of implantable cardioverter-defibrillator or pacemaker, septal myectomy or septal myocardial ablation; 4. meet the criteria of implantation of implantable cardioverter-defibrillator or pacemaker, septal myectomy or septal myocardial ablation; 5. impaired life-span expectancy due to cancer or other clinical conditions;

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Outcome
Type Measure Description Time frame Safety issue
Primary MACE composite a composition of cardiac death, readmission for heart failure, and cardiac infraction within 24 months' follow-up
See also
  Status Clinical Trial Phase
Terminated NCT03249272 - Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Phase 4
Recruiting NCT03846297 - Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
Completed NCT02806479 - Hypertrophic Cardiomyopathy Pilot Study
Active, not recruiting NCT01225978 - Refining Information Technology Support for Genetics in Medicine N/A
Completed NCT00001632 - Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease N/A
Completed NCT00001534 - Long Term Effects of Enalapril and Losartan on Genetic Heart Disease N/A
Enrolling by invitation NCT04050579 - OPIE in the Thin Interventricular Septum N/A
Completed NCT03537183 - Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy? N/A
Completed NCT02590809 - Hypertrophic Cardiomyopathy Symptom Release by BX1514M Phase 2
Completed NCT00001396 - Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop... Phase 1
Active, not recruiting NCT03723655 - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Phase 2/Phase 3
Completed NCT05135871 - Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects Phase 1
Completed NCT04129905 - Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies N/A
Recruiting NCT03061994 - Metabolomic Study of All-age Cardiomyopathy N/A
Completed NCT02234336 - Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Not yet recruiting NCT03706001 - Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression N/A
Recruiting NCT06169358 - Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
Not yet recruiting NCT04090437 - HCM-AF Ablation With ACUTUS N/A
Completed NCT04402268 - Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy